NeuroprotectionResearch Market

Pinealon

A synthetic tripeptide (Glu-Asp-Arg) developed by the Khavinson group as a pineal gland bioregulator, studied for neuroprotective and geroprotective effects.

Brain HealthNootropicBioregulatorKhavinson

Also referenced as: EDR, Glu-Asp-Arg

Also appears in: Longevity

Price compare
63 tracked offers across 63 vendors · 17 dosages
Best trust-adjusted value: Peptuvia · Strong trust · $0.82/mg
From
$0.82/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

-58.6%vs. Aug 10
Current low$0.82/mg
Market median$3.80/mg
Current coverage34 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Pinealon crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence90 certificate records mentioning this compound or product name47 provider-linked · 79 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Neuroprotection

Primary research area: Neuroprotection. Also surfaces under Longevity for browsing and discovery.

Aliases
2

EDR, Glu-Asp-Arg

Signal depth
Medium

No FDA label signal · 21 trials · 1201 PubMed results

Preclinical
Research evidence

Current evidence for Pinealon is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Pinealon has no clinical trials that name it and 1201 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
The Plant Journal · 529 citationsSimultaneous modification of three homoeologs of Ta EDR 1 by genome editing enhances powdery mildew resistance in wheatDesalination · 244 citationsPilot studies on high recovery BWRO-EDR for near zero liquid discharge approachStructural and Multidisciplinary Optimization · 179 citationsEigenvector dimension reduction (EDR) method for sensitivity-free probability analysisJournal ArticleInvestigations of lead-free multilayer shielding for diagnostic radiology using Monte Carlo simulations.Journal ArticlexPEDition pain: protocol for a quasi-experimental before-after study of a public health campaign on chronic pain in the Ems Dollart Region.Journal ArticleDeveloping an interprofessional self-reflection logbook in reproductive health in low-middle income countries: educational design research.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is Pinealon?

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR), developed by Vladimir Khavinson’s research group at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to a class of short peptide bioregulators theorized to interact with DNA and regulate gene expression in a tissue-specific manner — in this case, targeting the pineal gland and central nervous system.

How it works

The proposed mechanism involves direct peptide-DNA interaction:

  • Gene regulation — Khavinson’s group has published data suggesting short peptides can penetrate cell nuclei and interact with gene promoter regions, modulating transcription (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
  • Melatonin synthesis — Pinealon is theorized to support pineal function and melatonin production, though direct evidence is limited to cell culture and animal models (Khavinson et al., Advances in Gerontology, 2012)
  • Neuroprotection — In cortical neuron cell cultures, EDR peptide reduced markers of oxidative damage and apoptosis (Khavinson et al., Peptides, 2014)

Research status

Published evidence comes primarily from Russian research groups:

  • Khavinson & Malinin (2005) described the concept of peptide bioregulation and tissue-specific short peptides (Neuroendocrinology Letters, 26(3):233–238)
  • Khavinson et al. (2011) reported that short peptides penetrate cell nuclei and interact with DNA (Bulletin of Experimental Biology and Medicine, 152(1):102–105)
  • Anisimov et al. (2001) showed life extension effects of epithalamin (a pineal peptide preparation) in rodent models (Mechanisms of Ageing and Development, 122(11):1437–1461)

No Western peer-reviewed clinical trials have been published. The evidence base is primarily preclinical and originates from a single research group.

Key considerations

  • Part of the Khavinson bioregulator peptide family, alongside Epitalon, Thymalin, and others
  • Published research is concentrated in Russian-language journals and a single research group, limiting independent replication
  • Available from research vendors as lyophilized powder or capsules (typically 10–20mg)
  • The peptide-DNA interaction mechanism proposed by Khavinson is not widely accepted in Western molecular biology